IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal

Publisher： Karger

E-ISSN： 1662-0631|6|3|784-789

ISSN： 1662-0631

Source： Case Reports in Gastroenterology, Vol.6, Iss.3, 2012-12, pp. : 784-789

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genomic Imprinting of IGF-II and H19 in Adult Human Pancreatic Tissues

By  

Digestion, Vol. 60, Iss. 5, 1999-08 ,pp. : 477-483

Karger

Access to resources Recommend Favorite

Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis

By  

Digestion, Vol. 83, Iss. 4, 2011-02 ,pp. : 275-282

Karger

Access to resources Recommend Favorite

Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 33, Iss. 6, 2015-0 ,pp. : 771-779

Karger

Access to resources Recommend Favorite

Zinc alters the kinetics of IGF-II binding to cell surface receptors and binding proteins

By McCusker Robert   Mateski Rebecca   Novakofski Jan  

Endocrine Journal, Vol. 21, Iss. 3, 2003-08 ,pp. : 279-288

Humana Press, Inc

Access to resources Recommend Favorite

Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 29, Iss. 3, 2011-08 ,pp. : 289-302

Karger

Access to resources Recommend Favorite